Iteos Therapeutics Inc (ITOS)

NASDAQ
25.29
-0.07(-0.28%)
  • Volume:
    98,615
  • Day's Range:
    24.73 - 25.39
  • 52 wk Range:
    16.21 - 52.43

ITOS Overview

Prev. Close
25.36
Day's Range
24.73-25.39
Revenue
539.01M
Open
25.01
52 wk Range
16.21-52.43
EPS
9.32
Volume
98,615
Market Cap
896.14M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
427,210
P/E Ratio
3.01
Beta
1.5
1-Year Change
2.92%
Shares Outstanding
35,575,323
Next Earnings Date
Nov 17, 2022
What is your sentiment on Iteos?
or
Vote to see community's results!

Iteos Therapeutics Inc Company Profile

Iteos Therapeutics Inc Company Profile

Employees
74

Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company’s product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2AR antagonists that is in Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1/2 clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity. Iteos Therapeutics, Inc. was founded in 2011 and is headquartered in Watertown, Massachusetts.

Read More

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesBuySellSellSellNeutral
Technical IndicatorsSellSellStrong BuySellStrong Sell
SummaryNeutralSellNeutralSellSell